StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)

Investment analysts at StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a report released on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys has a 1 year low of $0.01 and a 1 year high of $1.99. The company has a market capitalization of $833,000.00, a PE ratio of -0.01 and a beta of -0.90.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.